Gray Market Peptides: So Much Hype, So Little Data BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved BPC 157: The peptide with big claims and scant evidence STAT Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law